Edition:
United States

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

234.20DKK
11:59am EDT
Change (% chg)

kr.0.70 (+0.30%)
Prev Close
kr.233.50
Open
kr.233.00
Day's High
kr.235.60
Day's Low
kr.231.30
Volume
3,976,655
Avg. Vol
3,926,573
52-wk High
kr.384.80
52-wk Low
kr.218.20

Latest Key Developments (Source: Significant Developments)

Dong Energy to build biogas plant for Novo Nordisk, Novozymes residues
4:18am EDT 

Dong Energy : Says will in cooperation with Bigadan build a large-scale biogas plant . The plant will reuse residues from production facilities of Novozymes and Novo Nordisk in Kalundborg, Denmark . Construction of the new biogas plant will commence in March 2017, and the plant is scheduled for commissioning already in the spring of 2018 .The biogas plant will have a production capacity of 8 million square metres of natural gas per year, corresponding to the consumption of around 5,000 households.  Full Article

Novo A/S has no plans to buy more Evotec shares
Wednesday, 15 Mar 2017 12:06pm EDT 

Evotec AG : Novo A/S does not intend to obtain further voting rights by acquisition or any other way . Novo A/S does not intend to influence composition of issuers' administration, management or supervisory board . Novo A/S does not intend to change capital structure of evotec, especially with regards to ratio of internal/outside financing and dividend policy Further company coverage: [EVTG.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

BRIEF-Riis says to head Falck after leaving Novo Nordisk
Wednesday, 1 Mar 2017 05:30am EST 

Novo Nordisk A/S : Outgoing Novo Nordisk North America head Riis said he taking the role of Chief Executive of Danish emergency services group Falck .Riis says was disappointed to have missed out on CEO's job at Novo Nordisk last year.  Full Article

Novo Nordisk replaces head of North America operations
Wednesday, 1 Mar 2017 01:17am EST 

Novo Nordisk : Says Jakob Riis, executive vice president, head of North America operations and president of Novo Nordisk Inc. has resigned from company .Effective today, Doug Langa, senior vice president for market access, Novo Nordisk Inc., has been appointed senior vice president, head of North America operations.  Full Article

Novo Nordisk proposes Novo A/S CEO and former BG chief as board members
Friday, 24 Feb 2017 02:02am EST 

Novo Nordisk : Says the board of directors proposes election of Kasim Kutay and Helge Lund as new members of the board of directors at the annual general meeting . Kutay is CEO of Novo A/S, the holding company for the Novo group . "The Board of Directors recommends election of Mr Kutay primarily because of his extensive experience as financial advisor to the pharmaceutical, biotechnology and medical device industries" . Lund is former chief executive officer of BG and Statoil . "The Board of Directors recommends election of Mr Lund primarily because of his extensive executive and board experience in large multinational companies headquartered in Scandinavia within regulated markets and significant financial knowledge" .Proposes re-election of the following board members elected by the Annual General Meeting: Göran Ando (chairman), Jeppe Christiansen (vice chairman), Brian Daniels, Sylvie Grégoire, Liz Hewitt and Mary Szela.  Full Article

Evotec says will issue 13.1 million new shares to Novo A/S
Thursday, 9 Feb 2017 03:34pm EST 

Evotec Ag : Novo A/S becomes new long-term strategic shareholder in Evotec . It resolved on a capital increase from its authorised capital against cash . Evotec will issue 13.1 million new shares to Novo A/S .Novo A/S will invest eur 90.3 m to subscribe shares of evotec at a share price of eur 6.87 per share.  Full Article

Novo Nordisk CEO: We are not concerned about Trump
Thursday, 2 Feb 2017 02:20am EST 

Drugmaker Novo Nordisk CEO Lars Fruergaard Jorgensen made the following comments during a call with journalists:. Two days ago the U.S pharma CEOs met with the Trump administration... Overall I felt it was a positive meeting. There was a lot of talk about the importance of investments and innovation," he said .. Novo Nordisk was not participating in the meeting .. "What Trump is after in terms of commitment and investments, Novo Nordisk is fully committed to and we decided to do it way before Trump took over, so we are not concerned about Trump." .. "We all see that there is a lot of discussion about drug pricing in the U.S. We feel relatively comfortable for our prices for 2017 as such but it is just a more unpredictable environment that we operate in" Further company coverage: [NOVOb.CO] (Reporting by Stine Jacobsen) ((stine.jacobsen@thomsonreuters.com;)).  Full Article

Novo Nordisk cuts 2017 sales, profit outlook in local currencies
Thursday, 2 Feb 2017 01:30am EST 

Novo Nordisk : Says 2017 sales growth is expected to be in the range of a decline of 1 percent to a growth of 4 percent measured in local currencies . Says 2017 operating profit growth is expected to be in the range of a decline of 2 percent to a growth of 3 percent measured in local currencies . Says for 2017, reported sales growth is expected to be 1-6 pct measured in Danish crowns, positively impacted by currencies of 2 percentage points . Says reported operating profit growth is expected to be 0-5 pct measured in Danish crowns, positively impacted by currencies of 2 percentage points . Says at annual general meeting on 23 March 2017, board of directors will propose a final dividend of DKK 4.60 for 2016 per share of DKK 0.20 . Says expected total dividend for 2016 of DKK 7.60 per share, of which DKK 3.00 per share was paid as interim dividend in august 2016, corresponds to an increase of 19% compared to 2015 . Says board of directors furthermore intends to initiate a new 12-months share repurchase programme of up to DKK 16 billion . Q4 operating profit 11,206 million DKK versus 11,418 million DKK seen in Reuters poll . Q4 sales 29,572 million DKK versus 29,495 million DKK seen in Reuters poll .Says 2017 capex around DKK 10 billion.  Full Article

Novo Nordisk CEO questions if company has the right R&D strategy
Thursday, 1 Sep 2016 05:49am EDT 

Chief Executive Lars Rebien Sorensen, Novo Nordisk A/S : Says pricing environment in the United States is becoming more difficult for pharmaceutical companies . Questions if company has the right research and development strategy in the US . Questions if it make sense to make the fifth generation of insulin analogues Further company coverage: [NOVOb.CO] (Copenhagen newsroom) ((copenhagen.newsroom@thomsonreuters.com; +45 33 96 96 55;)).  Full Article

Caverion delivers project for Novo Nordisk's new insulin production facility
Friday, 5 Aug 2016 03:00am EDT 

Caverion Oyj : Caverion delivers a project for Novo Nordisk's new insulin production facility in Hillerød, Denmark . Facility will produce medicines for treatment of diabetes and obesity . Project started in June 2016 and ends in February 2017 . Contract has a volume of approximately 5.4 million euros ($6.02 million) .Builder is Novo Nordisk A/S Full Article

More From Around the Web

BRIEF-Denmark's Novo Nordisk will not turn into big M&A machine-CEO

March 23 The CEO of Novo Nordisk's, the world's biggest diabetes company, made the following comments at the firm's annual general meeting on Thursday: